Trial for new bleeding disorder pill withdrawn before starting
NCT ID NCT06291415
Summary
This was an early-stage study to test the safety and find the right dose of a new oral drug called HMPL-523 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The study was designed to enroll adults whose ITP had not been fully controlled by at least one prior treatment. However, the trial was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Canberra Hospital
Canberra, Australia
-
Center for Cancer and Blood Disorders
Bethesda, Maryland, 20817, United States
-
Charite university
Berlin, 10117, Germany
-
Childrens Hospital of California
Irvine, California, 92868, United States
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
East Carolina University, Brody School of Medicine
Greenville, North Carolina, 27834, United States
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center
Georgetown, Delaware, 20007, United States
-
Hospital Gregorio Maranon Madrid
Madrid, 28007, Spain
-
Hospital Infanta Leonor
Madrid, 28031, Spain
-
Hospital Morales Meseguer
Murcia, 30008, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital del Mar Barcelona
Barcelona, 08003, Spain
-
Marien Hospital Dusseldorf
Düsseldorf, 40479, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, 74146, United States
-
Oslo University Hospital
Oslo, Norway
-
Peninsula Private Hospital
Frankston, Victoria, Australia
-
Royal Adelaide Hospital
Adelaide, Australia
-
San Juan Oncology Associates
Farmington, New Mexico, 87401, United States
-
Sykehuset Ostfold Kalnes (fosta) / Osfold Hospital Trust (MSL)
Grålum, 1714, Norway
-
Taussig Cancer Institute
Cleveland, Ohio, 44106, United States
-
Texas Oncology San Antonio Medical Center
San Antonio, Texas, 78240, United States
-
The Perth Blood Institute (PBI) Hollywood Specialist Centre
West Perth, Western Australia, Australia
-
UMG Gottingen Hämatologie
Göttingen, Germany
-
University Hospital of Schleswig-Holstein, Department of Haematology and Oncology
Lübeck, Germany
-
University de Burgos
Burgos, 09001, Spain
-
University of Washington (UW) Medical Center
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.